Canada - English
Canada - Français
New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0 to 25.
For a refined risk estimateof local recurrence
The Oncotype DX GPS assay is fully covered by Medicare for localized prostate cancer patients.
Nuclear-specific vs. nuclear-agnostic AR-V7 testing
Help Stage II colon cancer patients understand the power of genomics
Your Oncotype DX score can help you decide.
Oncotype DX has helped thousands of women find out.
When Dan's Colon Recurrence Score came back low, he decided against chemotherapy.
View Drs. Rick Baehner and Josh Routh's webinar reviewing the Oncotype MAP™ Pan-Cancer Tissue Test: Validation and Clinical Utility in Solid Tumors from a Pathologist's Perspective.
You can still see Drs. Rick Baehner and Josh Routh present “Oncotype MAP Pan-Cancer Tissue Test: Best Practices for Decalcifying Bone Samples in Preparation for Genomic Profiling”.
Dr. Gautam Jayram discusses the advantages of the Oncotype MAP Pan-Cancer Tissue test for advanced prostate cancer patients: "Genomic Profiling to Aid Therapy Selection for Metastatic Prostate Cancer Patients".
Have questions? We're here to help.